Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies July 14, 2026 8:30 AM EDTCompany...

Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies July 14, 2026 8:30 AM EDT Company Participants Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Peter Ordentlich - Co-Founder & Chief Scientific Officer Sharon Klahre - Vice President of Investor Relations & Communications Conference Call Participants John Crispino Kevin Strang - Goldman Sachs Group, Inc., Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Faisal Khurshid - Jefferies LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Stephen Sabba Xiaochuan Dai - UBS Investment Bank, Research Division Ellen Horste - TD Cowen, Research Division Toby Maher Philip Nadeau - TD Cowen, Research Division Joyce Zhou - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Michael Eck Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Conversation Michael Metzger CEO & Director All right.

Good morning, everyone. We're going to get started. So it's my pleasure to welcome you this morning.

My name is Michael Metzger, I'm the CEO of Syndax. A warm welcome to everybody joining us in person today and also online. We're thrilled to give you an update on our progress as we advance innovation for patients and bring more opportunities for great therapies to patients.

So we will be making forward-looking statements. Here is our disclosure. Syndax is a company on the move.

We're driving innovation and long-term value for patients. And we have what a few companies our size have in terms of accomplishments. We've gotten drugs approved actually and brought them to market.

So we are a fully integrated commercial organization now with a track record of success, and we're looking to expand on that success. We've built world-class R&D capability, both in the company and